New Drug Combination Significantly Slows Progression of Prostate Cancer with BRCA Mutations, Major Trial Finds

A newly published international clinical trial has shown that combining the PARP inhibitor niraparib with standard hormone therapies abiraterone and prednisone cuts the risk of disease progression by about half in men with advanced prostate cancer carrying BRCA mutations. Led by Professor Gerhardt Attard of the Cancer Institute at University College London and involving 696 patients across 32 countries, the results, published in Nature Medicine, could fundamentally shift the approach to treating this aggressive cancer subtype, offering new hope for individuals and clinicians worldwide.​

Key Findings: Drug Combo Offers New Hope

The phase 3 AMPLITUDE trial recruited men with metastatic castration-sensitive prostate cancer (mCSPC) whose tumors revealed alterations in the DNA repair pathway—specifically focusing on those with BRCA1 or BRCA2 mutations. Participants received either the combination of niraparib, abiraterone, and prednisone or standard therapies alone. The headline outcome: in the group with BRCA mutations, the addition of niraparib halved the risk of radiographic disease progression or death (hazard ratio 0.52), with the median progression-free survival not reached at final analysis, compared with 26 months in the standard care arm. In the overall study population, the combination reduced the risk of progression by 37%.​

Doctors use radiographic progression-free survival (rPFS)—time until scans show new or worsening cancer or patient death—as a key endpoint in trials of this kind. The improved rPFS in this study suggests meaningful clinical benefit and supports earlier use of the combination, rather than waiting until hormone therapies stop working.​

Expert Commentary: Shift Toward Precision Oncology

“This study marks a significant advance for a subset of prostate cancer patients who traditionally face a faster progression and poorer outcomes,” said Professor Gerhardt Attard, who leads the Treatment Resistance Group at UCL Cancer Institute and is a widely recognized authority on advanced prostate cancer and molecular diagnostics. “We now have compelling evidence that routine genomic testing at diagnosis is crucial. By identifying those with HRR [homologous recombination repair] alterations, particularly BRCA mutations, we can tailor therapy and potentially prolong survival and quality of life for these individuals.”​

Independent experts echo this sentiment. Dr. Karen Knudsen, CEO of the American Cancer Society (not involved in the trial), noted, “This reinforces the movement toward precision medicine, where treatments are selected based on the molecular fingerprint of a patient’s tumor.” She also underscored that the combination’s most pronounced effect was limited to those with BRCA mutations, advocating caution when generalizing results to broader groups.

Background: Genetics and Prostate Cancer

BRCA1 and BRCA2 are genes best known for their link to hereditary breast and ovarian cancer, but mutations in these DNA repair genes also confer a substantial lifetime risk of aggressive prostate cancer. Depending on the population studied, between 11% and 27% of men with metastatic prostate cancer carry mutations affecting DNA repair, with BRCA2 being the most common. Carriers of BRCA2 mutations can experience a three- to eightfold increased risk of developing prostate cancer when compared with the general population.​

Standard frontline therapies—such as androgen-deprivation therapy (ADT) and abiraterone (which further blocks androgen synthesis)—are effective for many. However, BRCA-mutant cancers tend to be more aggressive and less responsive, creating a significant need for more effective treatments for this population.​

How the Drug Combination Works

Niraparib is a PARP (poly ADP-ribose polymerase) inhibitor, a class of medications that blocks an enzyme cancer cells use to repair broken DNA. When this pathway is blocked in cancer cells that already have a faulty BRCA gene, the tumor’s ability to recover from critical DNA damage is shut down, leading to cell death—a concept termed “synthetic lethality”.​

Abiraterone, meanwhile, impedes the production of androgens, hormones that drive prostate cancer growth. By pairing these drugs, the therapeutic assault is two-pronged: attacking the tumor’s hormone dependence and its defective DNA repair machinery at the same time.​

Public Health Implications

The findings support routine genetic testing for DNA repair gene mutations, including BRCA1/2, for all patients diagnosed with advanced prostate cancer. Early detection allows for precision targeting with combination therapies, which could lengthen the period before the cancer becomes resistant to standard treatments.​

This trend toward genetically informed therapy is expected to become more prominent as more therapies are matched to a patient’s underlying tumor biology. For men and families with a history of BRCA mutations, early screening and genetic counseling may become even more essential in guiding treatment and surveillance decisions.​

Safety, Limitations, and Counterpoints

While the new regimen was effective, it carried higher risks of significant side effects—notably anemia, high blood pressure, and the need for blood transfusions in about a quarter of patients receiving the combination. Rare but severe events, such as myelodysplastic syndrome, were also reported, necessitating ongoing safety monitoring.​

A key limitation is that the combination’s greatest benefit was seen only in patients with BRCA-mutant tumors. In individuals with other alterations in the DNA repair pathway, the effect was smaller and not statistically significant. Furthermore, long-term effects on overall survival remain to be established, as the median follow-up in the trial was just over 30 months and many patients in the control group eventually received additional therapies, possibly diluting the observed benefit.​

Experts stress that patients and providers must engage in shared decision-making, weighing the promise of delayed progression against the risks of side effects.

Practical Advice for Readers

For patients and caregivers, these findings underscore the importance of speaking to oncologists about genetic testing, especially for those with a family or personal history of advanced prostate cancer or early-onset disease. If classified as eligible, individuals may discuss participation in ongoing clinical trials or inquire about the availability of approved PARP inhibitor-based regimens.

Professional organizations such as the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) already recommend genetic testing for men with metastatic prostate cancer, and these new findings will likely reinforce those guidelines.

Medical Disclaimer

“Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.”

References